New leadership advances Cerebra’s mission to transform the future of sleep diagnosis and therapy, globally
Brian Hayward, Board Chair of Cerebra, a leader in sleep science, today announces the appointment of Nicholas Kosciolek to the role of CEO.
Kosciolek brings international leadership and a proven track record for driving profitable growth in MedTech start up and growth stage companies. Under Kosciolek’s leadership, Cerebra will advance its mission to transform the diagnosis and treatment of major sleep disorders, including insomnia, which remains largely unsolved.
Cerebra digital sleep analytics move beyond traditional scoring methods and sleep staging, providing automated, digital and detailed analysis of brain activity during sleep. Sleep experts believe that this is the crucial first step in bringing precision medicine into the world of sleep diagnostics creating the opportunity to personalize effective treatments.
“Nick’s deep experience in commercializing sleep products and services, as well as his experience with organizational scale-up and geographic expansion will be essential to the next stage of Cerebra’s growth”, said Hayward.
“Joining Cerebra is an incredible opportunity to start with a proven technology that fills a massive market need,” says Kosciolek. “Cerebra’s proprietary technology provides a level of understanding of sleep we’ve never seen before. It’s been validated and adopted by researchers and institutions worldwide including NASA, Harvard University and University of Pennsylvania. We’re at an inflection point—our focus will be on growth and the full-scale adoption of this technology across the sleep industry. We need to get Cerebra technology into as many of the right hands to have the global impact needed in sleep diagnosis and therapy.”
This exciting appointment follows years of leadership and development by the entire team at Cerebra, and continues the commitment of its founders to innovation in this growing field. The Cerebra team is supported by its Scientific Advisory Board, made up of the world’s leading sleep scientists who will offer their experience in the study of sleep, sleep disorders, diagnosis and therapy to help Cerebra continue to evolve the future of sleep science.
“As a board, we recognize Cerebra is in the strong position it’s in today thanks to the vision of Dr. Madgy Younes, Scientific Founder, and Earl Gardiner, Co-Founder”, stated Hayward. They have been central in developing, validating and commercializing the technology and driving early adoption among the research community. We look forward to their continued support and guidance. The board particularly appreciates Earl’s leadership as CEO over the past year, leading Cerebra’s management team—working in partnership with the board—to sharpen our strategic focus”, added Hayward. “Earl will be working closely to support Nick over the next few months, to ensure a smooth transition and successful completion of Cerebra’s financing round.”
For more information, contact:
289 440 2654
Cerebra Health Inc. (Cerebra) is a Canadian digital health and virtual care company transforming the future of sleep diagnosis and therapy. Cerebra digital sleep analytics are used by researchers and clinicians around the world to gain greater insight into an individual’s sleep and enable the personalization of treatments for sleep disorders.
Cerebra Medical, a wholly owned subsidiary of Cerebra Health, operates an ISO 13485:2016 certified Quality Management System for the design, development, and manufacture of EEG sleep monitoring systems and medical device software for collection and analysis of physiological data recorded during sleep. Cerebra Medical holds an MDSAP certificate in conformance with the requirements of Health Canada and FDA.
About Nicholas Kosciolek
Nicholas Kosciolek brings 20+ years of experience in the Sleep and Respiratory industry, as well as extensive international experience having conducted business in 45+ countries. As President and CEO of Sky International Management Group, Nicholas provided visionary leadership to numerous start-up companies, most recently as COO of a medical device company focusing on sleep apnea. In addition, Nicholas held the position of Vice President International Americas at Philips/Respironics, Managing Director Profile Pharma, and Group Controller at Aventis Pharmaceuticals.